A cornerstone of the Inflation Reduction Act (IRA) of 2022 is the Medicare Drug Price Negotiation Program, which empowers the Centers for Medicare & Medicaid Services (CMS) to directly negotiate prices for a select number of high-expenditure Part D and, beginning in 2028, Part B drugs
